ETV6::RUNX1 Acute Lymphoblastic Leukemia: how much therapy is needed for cure?

Area of Science:

• Pediatric Oncology
• Hematology
• Clinical Trials

Background:

• ETV6::RUNX1 fusion gene is a common genetic abnormality in childhood Acute Lymphoblastic Leukemia (ALL).
• Current treatment protocols achieve high survival rates (>95% at 5 years) but are associated with significant long-term side effects.
• Understanding the relationship between cumulative drug doses, treatment intensity, and outcomes is crucial for optimizing therapy and minimizing toxicity.

Purpose of the Study:

• To provide an overview of cumulative drug doses and treatment intensities across eight international trials for ETV6::RUNX1 ALL.
• To characterize the therapy required for achieving cure in this specific leukemia subtype.
• To perform a meta-analysis summarizing survival outcomes (5 and 10 years) and to explore potential for treatment de-escalation.

Main Methods:

• A meta-analysis was conducted on data from eight international clinical trials involving ETV6::RUNX1 ALL.
• Trials were categorized into two groups (A and B) based on the percentage of patients in the low-risk (LR) group.
• Survival outcomes and treatment characteristics (cumulative drug doses, intensity of asparaginase, glucocorticoids, and vincristine) were compared between trial groups and risk strata.

Main Results:

• Meta-analysis showed no significant heterogeneity in survival outcomes for low and medium-risk patients in trial group A, despite variations in treatment intensity.
• Statistical heterogeneity was observed in trial group B for low and medium-risk patients.
• Higher cumulative doses and intensity of asparaginase, glucocorticoids, and vincristine were associated with improved 5-year event-free survival but not overall survival.

Conclusions:

• Despite differences in treatment intensity, similar survival outcomes were observed across some trials, particularly in trial group A.
• The findings suggest that current treatment intensity may exceed what is necessary for optimal outcomes in ETV6::RUNX1 ALL.
• Future research should focus on investigating the feasibility of de-escalating therapy to reduce treatment-related side effects without compromising survival.